Gemini Therapeutics, Inc. (GMTX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of FS Development Corp., which merged with Gemini Therapeutics, Inc. (“Gemini” or “the Company”) (NASDAQ: GMTX) on February 5, 2021. Such investors who continue to hold to the present are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether FS Development Corp. failed to provide relevant information to its shareholders before the merger.
If you are aware of any facts relating to this investigation or hold Gemini shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.